MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.690
+0.050
+1.08%
Opening 14:24 01/20 EST
OPEN
4.600
PREV CLOSE
4.640
HIGH
4.738
LOW
4.540
VOLUME
112.35K
TURNOVER
--
52 WEEK HIGH
12.00
52 WEEK LOW
4.150
MARKET CAP
62.36M
P/E (TTM)
-4.3119
1D
5D
1M
3M
1Y
5Y
Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy
Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study. Approval of the company's Phase ...
Benzinga · 01/13 14:55
Edesa Biotech secures Canadian approval to test COVID-19 drug as rescue therapy
Edesa Biotech (NASDAQ:EDSA) has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in Phase 3 part of
Seekingalpha · 01/13 13:57
Edesa Biotech Receives Canadian Approval To Test COVID-19 Drug As Rescue Therapy
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company has received approval from Health Canada to test its
Benzinga · 01/13 13:03
EDSA: Important Inflection Points Likely in 2022…
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT
Benzinga · 01/11 09:10
Edesa Biotech EPS beats by $0.10
Edesa Biotech (NASDAQ:EDSA): FY GAAP EPS of -$1.10 beats by $0.10. Press release At September 30, 2021, Edesa had working capital of $10.63M. Cash and cash equivalents totaled $7.84M. 
Seekingalpha · 12/29/2021 09:19
Recap: Edesa Biotech Q4 Earnings
Edesa Biotech (NASDAQ:EDSA) reported its Q4 earnings results on Tuesday, December 28, 2021 at 04:15 PM. Here's what investors need to know about the announcement.
Benzinga · 12/28/2021 23:29
Edesa Biotech Reports Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2021 ...
ACCESSWIRE · 12/28/2021 21:15
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021
 
Benzinga · 12/20/2021 16:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDSA. Analyze the recent business situations of Edesa Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EDSA stock price target is 18.00 with a high estimate of 20.00 and a low estimate of 16.00.
High20.00
Average18.00
Low16.00
Current 4.690
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 24
Institutional Holdings: 385.50K
% Owned: 2.90%
Shares Outstanding: 13.30M
TypeInstitutionsShares
Increased
7
99.56K
New
7
48.36K
Decreased
0
0
Sold Out
2
23.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Non-Executive Chairman/Independent Director
Sean Macdonald
President
Michael Brooks
Chief Executive Officer/Secretary/Director
Pardeep Nijhawan
Chief Financial Officer
Kathi Niffenegger
Director
Frank Oakes
Independent Director
Lorin Johnson
Independent Director
Paul Pay
Independent Director
Carlo Sistilli
Independent Director
Peter van der Velden
No Data
About EDSA
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. It is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.